This action might not be possible to undo. Are you sure you want to continue?
Use ISSN#1078-6791. To subscribe, visit alternative-therapies.com
Stanislaw R. Burzynski, MD, PhD: Novel Cancer Research and the Fight to Prove Its Worth
Interview by Karen Burnett Stanislaw R. Burzynski, MD, PhD, graduated with distinction from the Medical Academy in Lublin, Poland, in 1967. During the same year he identified naturally occurring peptides in the human body which he concluded control cancer growth. He found that there is a marked deficiency of these peptides in cancer patients. In 1968, he earned his doctorate in biochemistry. From 1970 to 1977, while a researcher and assistant professor at Baylor College of Medicine in Houston, his research was sponsored and partially funded by the National Cancer Institute. At Baylor, he authored and coauthored 16 publications, including five concerning his research on peptides and their effect on human cancer. Four of these publications were also coauthored by other doctors associated with MD Anderson Hospital and Tumor Institute and Baylor College of Medicine. It was at Baylor that Dr Burzynski named these peptides “antineoplastons” due to their activity in correcting and normalizing neoplastic, or cancerous, cells. In 1977, Dr Burzynski founded his clinic in Houston where he’s since treated over 15 000 patients. He is also the president of the Burzynski Research Institute, where he continues to pursue scientific research on antineoplastons. He is the author and coauthor of over 300 scientific publications and presentations. He holds 242 patents registered in 35 countries, related to proprietary scientific inventions. Alternative Therapies in Health and Medicine (ATHM): Please tell us about your education in Poland and how you became interested in researching the science of cancer. Dr Burzynski: In Poland, my main interest initially was biochemistry. When I entered medical school, I was determined to proceed with research in biochemistry at the same time as I was studying medicine. Before I even started at the Medical Academy in Lubin, Poland, I was quite involved in chemical experimentation. During my high school days, I spent a lot of time in chemical laboratories and participated in something called Chemical Olympics, which was the high school students from all over the country competing once a year. I was able to go to the top of these Olympics at the national level. So I carried a lot of interest in chemistry since the high school years and, obviously, wanted to continue this in my medical university. And that’s what I did from the first grade of the curriculum, or first class. And I was very fortunate because after I graduated—after I finished my first grade, the professor offered me the position of teaching assistant, which was very unusual—a second-grade student also teaching grade-one students. I was giv54
ing lectures. I was participating in practical exercises in chemistry and so on. At the same time, I began receiving a substantial salary, which was also very unusual. So during my medical education, I also was able to be quite productive in the area of biochemistry. When I came to the end of my medical education—I graduated in 1967 and received a diploma with distinction, first in the entire class—I had published a number of publications in international biochemical journals. At that time, I had edited about 14 publications and had presented abstracts at congresses. So it was logical that I should do a doctoral dissertation, which again was very unusual. In the European tradition, you do this many years after graduation from medical school—probably 15 or 20 years—after you already have a lot of experience. Since I already was quite advanced in the research, I proceeded with doctoral work. It was during this work that I discovered new chemicals in human blood. I was working on amino acids in blood, but I discovered additional chemicals, which were giving similar reactions to amino acids, and I identified them as peptides. Nobody before knew that these peptides ever existed in blood; I was the first one to discover them. Since I was approaching my examinations for the doctorate and public defense of the doctoral dissertation, I wanted to make sure that I further identified these peptides, which nobody knew before. I was afraid that I would have some tough questions from the professors during my defense and also during public presentation of my work. So I proceeded further in the identification of these newly discovered chemicals and found that they were almost deficient—they were almost completely gone—in the blood of patients who had advanced cancer. This was the first time I found some correlation between cancer and the newly discovered chemicals existing in normal human blood. Logically, I thought that such deficiency in advanced cancer patients perhaps had something to do with anticancer activity of these newly discovered peptides. But at that time, in Poland there were not enough resources to study this further. So I successfully obtained the doctorate in biochemistry a year after my graduation from medical university and proceeded in my work to characterize these newly discovered peptides. By the time I came to the United States in 1970, I already had found 39 peptide fractions in blood. I brought with me the samples and I was looking for the possibility to test these samples for their
Conversations With Stanislaw R. Burzynski, MD, PhD
ALTERNATIVE THERAPIES, MAY/JUNE 2012, VOL. 18, NO. 3
PhD . MD. and I identified them as peptides. but I discovered additional chemicals. —Stanislaw R. I was working on amino acids in blood. … I proceeded further in the identification of these newly discovered chemicals and found that they were almost deficient—they were almost completely gone—in the blood of patients who had advanced cancer.com. which were giving similar reactions to amino acids.This article is protected by copyright. Burzynski. visit alternative-therapies. I was the first one to discover them. Use ISSN#1078-6791. please visit copyright. To subscribe.com I discovered new chemicals in human blood. … Nobody before knew that these peptides ever existed in blood. To share or copy this article.
but the results were quite remarkable. Despite this. To share or copy this article. and I immediately started work on both brain peptides and peptides from the blood. which was remarkable because such a thing did not exist before. There were 22 patients in phase I and four of them developed what is classified as complete response. which means that the tumors disappeared completely—very unusual for a phase I clinical trial. And we discovered that it could be done. it has nothing to do with urine. The day after my birthday in 1971. in 1977. At the same time. The journal which published the results put the picture of the liver scan showing remarkable decrease of large metastatic tumors on the cover. Initially. visit alternative-therapies. So the first study was a great success. and for the next 5 years. But I realized that I would be medically attacked for using urine for isolation of peptides—the perception of urine was quite ugly—but on the other hand. Peptides that existed in blood were filtered through the kidneys into urine. I isolated peptides from blood. And there was a case of bladder cancer. Dr Georges Ungar. Burzynski. which I learned by myself. Then our attention switched from fractions isolated from urine. and urine was a much easier. It’s been a long road to get to this point. VOL. Finally in 1972. to synthetic antineoplastons. Every sample he tested. Ultimately. obviously. They did not kill normal cell lines. We are no longer using this. I continued research at Baylor on peptides with anticancer activity. which were the objects of the first clinical trials. This was done together with the doctors from MD Anderson. This was his work and. and I felt somewhat humbled by this. I have constantly been accused of using urine for treatment of patients. in summary. These were tough cases: for instance. Since 1980. I was able to build a substantial laboratory with new equipment. This enabled me to move further and to try to put together an application for a grant through the National Cancer Institute (NCI). I met with my friend from MD Anderson Cancer Center. The operation developed very well and I received a promotion to assistant professor at Baylor College of Medicine. our attackers don’t stop. PhD ALTERNATIVE THERAPIES. initial phase I clinical trials were performed a long time ago. what was even more important was that the professor who employed me. So that. we have done a lot of research on synthetic antineoplastons and decided to discontinue research on fractions isolated from urine. Finally. This was very gracious. a remarkable thing occurred. is how it happened. My colleagues at MD Anderson were twice my age and they were wellknown professors. Use ISSN#1078-6791. But then. 18. this was the material that was readily available. However. ATHM: Despite controversy in the medical community and years of legal harassment by the board of medical examiners and the FDA. he found activity against cancer—various types of cancer which were very resistant to any therapy. these peptide fractions did not have any toxic effect. was very interesting. NO. wanted me to do research on peptides isolated from the brain. Twelve Oaks Hospital. I gave him the samples and as he began testing. The study was done at one of the top hospitals in Houston. To subscribe. which was also very advanced. 3 . Upon advice of Professor Ungar who was my boss at Baylor at that time. MAY/JUNE 2012. So this was great luck that I was offered a position in one of the top centers doing peptide research in the country. but at the same time he agreed that I could spend about 50% of my time working on my peptides that I discovered in Poland. we are simply obtaining them through the process of chemical synthesis.com biological activity. I received a grant from the NCI to study the peptides. on the first formulation of Antineoplaston A. It belonged to American International chain of hospitals. please visit copyright. MD. colon cancer which spreads to the liver. These are synthetic chemicals which are the same as those that exist in human blood.This article is protected by copyright. and we could have a lot of urine for my study. Such opportunity occurred in October of 1970 when I was given the position of research associate at Baylor College of Medicine in Houston. but I was the one who was supposed to direct the grant and give them certain tasks to perform. Even Conversations With Stanislaw R. How have your cancer patients responded to the treatment? Dr Burzynski: Well. January 23. we proceeded with further characterization of antineoplastons and I was able to reproduce at least some of these ingredients synthetically. I was able to make contact with the doctors from MD Anderson Cancer Center and they volunteered to test my peptide fractions on various cancer cell lines. such as malignant melanoma. Again. but it was very difficult to cap a sufficient amount of blood for such research.com. I had just come to the country and could barely communicate in English. So I decided to proceed and isolate the peptides from urine. of course. Obviously. available material for isolating these peptides. the grant which I received from the NCI was for further characterizations of peptides from urine which have anti56 cancer activities. the results of your research into antineoplastons as a treatment for cancer has progressed to phase III clinical trials. about when President Nixon proclaimed the war on cancer. I became principal investigator in the grant. I received substantial resources and was able to hire additional researchers to work with me. I began studying urine samples to see if we could isolate similar peptides from urine. This was at the beginning of 1971.
Japanese researchers presented the results of a controlled randomized clinical trial with patients who had advanced colon cancer which had spread to the liver. and at the same time. So this translates to human lives. and they are not finished. If the medical board would have received what they wanted in 1994. Recently. you see. The closer we come to the final victory. In the antineoplaston group. 18.com. It was very. If they win the right to discipline me. Both versions have been used in a large number of phase II clinical trials supervised by the FDA. We are attacked all the time by governmental agencies starting from county level. The other group received a combination of antineoplastons plus chemotherapy. NO. The most important thing is that we are saving the lives of numerous people. We are still being attacked by state agencies. Of course. the FDA persists in not permitting us any other type of clinical trials other than antineoplastons plus radiation therapy. such as the Texas Medical Board. The record is over 25 years. which means that survival of the antineoplaston group was about 62%. Fourteen phase II clinical trials are completed involving patients with incurable brain tumors who have successfully proven safety and efficacy. and the FDA also gave us what is called Orphan Drug Designation for all gliomas and these are all types of malignant brain tumors. We know very well that patients who previously used antineoplastons after radiation therapy had much shorter survival. People usually survive between 1 to 2 years then they die. So the FDA granted us permission to proceed with phase III trials of brainstem glioma. A travesty of justice. This harassment was dragging on for many. vs 6. visit alternative-therapies. how can you call it anything else? The patients have been cured. Five years is usually the milestone for saying that the patient was cured from the disease. We continued to develop a number of formulations and entered phase I with synthetic medication and then proceeded with phase II clinical trials. If we look into our project of phase II clinical trials which we did in brain tumors. We are saving lives of people. there were twice as many patients alive after 5 years. They will die. VOL. which I named Antineoplaston A10 and Antineoplaston AS2-1. For the first time in medical history. One group was treated with chemotherapy administered directly into the liver. inoperable brainstem glioma. then these 120 patients who have now survived over 5 years with malignant brain tumors wouldn’t survive today. Conversations With Stanislaw R. Burzynski. federal level. We have two patients with this type of tumor who are well and alive after 25 years without any sign of tumor. despite any treatments which have been used. we are very busy with brain tumors.7% when the patient is using radiation therapy. many years. 57 ALTERNATIVE THERAPIES. MD. which is a large number of patients considering that they were diagnosed with an incurable disease. but at the same time they informed us that we have to use antineoplastons plus radiation therapy. which is obviously remarkably higher. very difficult. you have to go to court.it was proven that this type of tumor can be cured. You really always have to have legal defense. So that’s where we stand now. it was about 34%. The patients who didn’t have any treatment. In 1984 we came out with the formulations of two intravenous antineoplastons. But it’s nothing unusual. About 35% of patients who did not have prior treatment and were diagnosed with inoperable brainstem glioma survived over 5 years. Use ISSN#1078-6791. Out of these 550 patients. these fourteen phase II clinical trials on incurable brain tumors. mAY/JUNE 2012. then 400 patients who are under treatment now would have nowhere to go. ATHM: Were there many patients that experienced this result? Dr Burzynski: This is not one patient. We did a lot of testing before that and also published the results. we are exposed to the fiercest attacks ever by the agency which should award us for saving the lives of hundreds of incurable cancer patients. Now we have only one phase II clinical trial. The patients who received radiation were dying later on from the tumor or from the delayed effect of radiation therapy. and whenever we have the best results. but at this moment. they blame me for using urine in the treatment of patients.This article is protected by copyright. and that’s what we like to do here.com now. PhD ATHM: Has antineoplaston treatment been better suited to certain cancers? Dr Burzynski: Our emphasis was brain tumors. Now we are at the end of this project. If the patient is surviving over 20 years without any sign of tumors. that’s stupid people motivated by some business or organization to slow us down. please visit copyright. In the future. you have to definitely try to stay alive and preserve enough money to do advanced clinical research. To share or copy this article. about 120 survived over 5 years. and many patients survived over 10 years and 15 years. the attacks greatly intensified after the FDA gave us permission for phase III clinical trials. We picked out the worst possible type of cancer for such clinical trials which is uniformly less than deadly. The Japanese researchers also presented the results of clinical trials in primary liver cancers as well as some studies on lung and breast cancers and brain tumors. This always happens when you’re approaching medical breakthrough and we are prepared to handle this. Dirty politics and harassment by agencies like the Texas Medical Board translate into human lives. the more vicious the attacks on us become. But still. ATHM: Did you have setbacks that caused you to change your treatment course? Dr Burzynski: Well. the attacks intensify. The “war” with the FDA lasted 14 years. state level. The “war” with the Texas Medical Board began around ‘84 and is still in full steam. To subscribe. And today nothing comes even close to such statistics because these tumors are uniformly deadly. But at the same time. and then we move into phase III clinical trials. we will start additional clinical trials in the other types of cancers. Our survival at 2 years is 56%. we treated about 550 patients in FDA-supervised clinical trials. they lived much longer. Only about 6% survive longer than 2 years and none survive over 5 years if the standard treatment is used with radiation therapy. We also see substantial survival over 5 years—above 35%. these are numerous patients. and in the group that received just the chemotherapy. other groups were performing clinical trials on different types of cancers. So our adversaries never cease. 3 . certainly. This should not happen today in the United States. Survival for children after diagnosis is usually 2 years. so it’s not easy. They would be dead because I would not be able to treat anybody. which is coming to the end.
which included three additional ingredients. PhD 58 ALTERNATIVE THERAPIES. and they continue to smear us whenever they can. and the NIH copied about 12 or 14 of these patents. W treatment of nine patients. some others would like to work with you. they were saying that the treatment was great—on the other hand. but what they were trying to do instead. I think they gave the institute about $15 million. We were the subject of numerous grand jury investigations. didn’t work. We were approached at the same time by Elan Pharmaceutical. NCI initially sponsored the clinical trial with Elan Pharmaceuticals focusing on one of the ingredients of antineoplaston.i defended mYself against the ridiculous attacks of the fda and then We finallY proved that this Was completelY frivolous. MAY/JUNE 2012. But then you have the pharmaceutical company ingredient. they sent a group of experts to review select cases of brain tumors. 3 . On one hand. He became deputy commissioner of the FDA. I defended myself against the ridiculous attacks of the FDA and then we finally proved that this was completely frivolous. and this provided valid answers to claims that the treatment failed. There were 243 patents for my inventions. of course. They got together with the NCI.com. They had never seen such great results in the treatment of brain tumors. At that point they were saying “Wow it’s a great medication. Obviously we don’t have good relations with them at all. Use ISSN#1078-6791. Finally in 1990. NO. If there was any case in history that conspiracy of the government and pharmaceutical companies is documented. ATHM: Clearly the pharmaceutical company played a role in the discrimination your company has faced. they decided to get out of the agreement. The doctor who worked with us at NCI suddenly went to the FDA. please visit copyright. Do you think you will ever partner with a company. And this group of experts really found remarkable results.com ATHM: How has your relationship with the NCI changed over the years? Dr Burzynski: Initially the relationship was good because we received a grant from the NCI. the NCI decided to sponsor clinical trials with antineoplastons in brain tumors. was steal my invention. In the patent for one of the ingredients of antineoplastons. The NCI was out to take away what I discovered and go together with Elan for monetary award. I had no way to proceed with my research.” At the same time they were saying that the real antineoplastons. We need the participation of pharmaceutical companies to expand research. To subscribe. VOL. They gave them dosages which were about 50 times lower. They diluted the medications with sterile water. That’s what they do. one of our companies became a pharmaceutical company because a few months ago. and once they started. The patients then developed side effects such as fluid overload. After we learned that what they did—and we had evidence because they measured the concentration of the ingredients of the antineoplaston in the blood—we forced them to stop after e Were the subject of numerous grand jurY investigations. the NCI did whatever they could to make sure that the trials would not be successful.. Then when the grant money stopped. They made the agreement. and finally. they were trying to put me in prison for life so that they could steal it from us. In the meantime. very well documented. 18. But after Elan Pharmaceuticals learned what we had. We obviously were delayed. the FDA gave us approval of the prescription Conversations With Stanislaw R. visit alternative-therapies. This is very. together with the pharmaceutical company. or are you forever discouraged by your experiences? Dr Burzynski: We see numerous pharmaceutical companies. It is obvious that I would not be able to develop such a big project globally without support. they wanted me to go to prison for life so that they could steal my invention. Clinical trials did not start until 2 years later. But still the animosity lasts. by giving the patients very low dosages of the medication. it’s working. Burzynski. The trials had a difficult start. Some of them would like to steal. MD. They were smearing us wherever they could. The treatment was discontinued after 1 or 2 months. And we are working now with pharmaceutical companies. That’s what happens.This article is protected by copyright. I used our attorneys to force them to stop because we didn’t want them to kill people just to prove that the antineoplastons don’t work. And then. How can we have good relations with thieves? Of course most of the people who were at the FDA at the time are no longer there. How could they do it? Well. So then they decided to work against me with the FDA. To share or copy this article. We were very happy with this. This is bad because they have to protect the American people. which wanted to work with us to sponsor clinical trials to speed up the approval process.. the NCI doesn’t like it. this is the case. They published the results in the Journal of the National Cancer Institute and after the visit. I had to continue with my own resources.
for practically every patient who comes for the treatment. we ask FDA what they will allow us to do. This is called gene-targeted therapy. please visit copyright. The right way to treat cancer is to treat the genes that are causing the cancer. it was always done this way. which costs us a lot of money. The other way is orally in tablet form. VOL. If you are talking about antineoplastons clinical trials. We have protocols for clinical trials and we know which dosage we need to use for certain indications. It’s called Compassionate Exception. When the patient comes. Annually. We only incurred huge expenses because of the stupid actions of the governmental agencies and that’s where we are now. Now everybody knows about it. as well as [introducing] some supplements. “Well. ATHM: Do you use different doses and different components or make-ups for the treatment? Dr Burzynski: Absolutely.” The people who hated us suddenly try to become the friends. Also for children and adults the dosage is different. When intravenous antineoplastons are given. PhD unfortunately intravenous antineoplastons are limited to clinical trials. We are independent and can do whatever we would like to do without being manipulated by the other agencies. but Conversations With Stanislaw R. ATHM: Do you recommend that your patients avoid chemotherapy and radiation before treatment with antineoplastons? Dr Burzynski: Well. Use ISSN#1078-6791. ATHM: How does the lack of governmental support affect your patients? Dr Burzynski: When patients come to us. want to put us out of business. And that’s typical when the paradigm shift happens. the patient receives a lot of intravenous fluid. Since phase II clinical trials now are coming to an end. we use other medications which work on the genes. most of them are treated in our oncology practice. that’s why we need to have a personalized approach. all of this disappears. then this money probably would come from the government. It’s going to be this way and then everybody will say. So it’s just up to the FDA. it is obvious. Only recently have the doctors become the slaves of organizations like the NCI or pharmaceutical companies. We try to help obtain payments from the insurance companies for them—they have insurance policies and for most of them.This article is protected by copyright. This is phenylbutyrate. and finally. I still have to deal with character assassinations from people working for the pharmaceutical cartels who have a lot of support from organizations which should help us but instead. But in this case. Burzynski. at times. For instance. Every case is somewhat different.com drug from the family of antineoplastons. One is intravenous. There are no long-term side effects—after the treatment is completed. we are using medication which is approved by the FDA. when the treatment with intravenous antineoplastons will be approved by the FDA—and in many other countries—the controversy will disappear. in our oncology practice where most of the patients are treated. insurance covers the treatment which is done here. the dosage could be different for a highly malignant brain tumor like glioblastoma and different for a tumor that is less active like low-grade glioma. mAY/JUNE 2012. We have to use a combination with the other medications because the activity of the oral antineoplastons is not as strong as intravenous. So the supplement will have no additional side effects compared to the side effects of chemotherapy. So we know what to do because we have used this for a long time. For instance. 3 . we provide medication free of charge. But it was not understood yet at that time that cancer is a disease of the genes. and they are currently giving permission for the patients who didn’t have prior radiation or chemotherapy. The cancers have names like breast cancer or lung cancer but what is really causing cancer is abnormality in our genes. so the main side effect is the disturbance of fluid balance and changes in mineral concentration. We prefer to use intravenous antineoplastons because they have much higher activity. But these things can be very easily corrected by simple adjustment of the fluid volume the patient is taking. visit alternative-therapies. there is a tendency toward lower potassium levels in blood and higher sodium levels. ATHM: Could you please describe the genomic and epigenomic principles behind your more recent research and their involvement in your cancer treatment program? Dr Burzynski: I published the review article in a peer-reviewed journal almost 20 years ago on the principles of personalized gene-targeted therapy. We need to identify 59 ALTERNATIVE THERAPIES. ATHM: What are the side effects of intravenous antineoplaston treatment? Dr Burzynski: There are some mild side effects. To share or copy this article. NO. Obviously. The patient may receive dietary support to increase potassium in their blood. and this is the most effective treatment. If you have support from the government. ATHM: Have you received any governmental financial help or partnerships? Dr Burzynski: We didn’t receive any. which is converted into one of the antineoplastons in the patient’s liver. But instead we have to generate the money through our business activities and use this money for the approval process. we ask the FDA for permission in order to treat this patient. we have to ask the FDA for permission to treat them. now we are at the mercy of the FDA. MD. Do not treat just the name of cancer. ATHM: Let’s talk about the science again. It can be done. we spend $5 to $6 million for this purpose. We are gradually moving in this direction. I would try to treat these patients without radiation or chemotherapy because radiation and chemotherapy for brain tumors can do a lot of damage. and we have a lot of experience. On the other hand. but 20 years ago. very few people realized it. 18. They don’t give permission for any other diagnosis—just for brain tumors. But in the meantime. In medical history. So this is severely limited. Plus. How do you administer antineoplastons? Dr Burzynski: There are two ways to do it. To subscribe.com.
That’s why we have great success in the treatment of incurable brain tumors. and then we would use the same medication for one patient’s breast cancer as well as another’s stomach cancer. this was heresy. But unfortunately. MAY/JUNE 2012. And this is something that is easily understandable. which work on different genes. and they can be used in combination with antineoplastons. But suddenly a year ago. it is. please visit copyright. It may happen that the same genes may cause breast cancer or stomach cancer.com. The gene may be turned off by epigenomic mechanisms. And also they turn off oncogenes. But it’s not diet as such. That’s how it works. We identify the genes which are causing the problem and treat the genes. Unfortunately. Do not treat just pneumonia by the same antibiotics. The silenced gene which was inactive now becomes active and will fight cancer. Now the same principles are being applied to the treatment of cancer. rather than just treating the name of the disease. 18. This is a complete analysis of the entire genome of 24 000 genes to find out which genes are active and which genes are not active. Diet is a combination of chemicals. you also find out which dietary ingredients make sense and which do not make any sense because they also work on the genes. MD.com changes in the genes and treat the genes which are “sick. they run the test. But this is really the science that is developing. When you use genomic analysis. Use ISSN#1078-6791. Some of these chemicals were isolated and now are available as chemotherapy drugs or gene-targeted therapy. it can work very well. Certainly. It contributes to billions of dollars in losses because typically the medications—single medications— work for less than 10% of patients.This article is protected by copyright. If the patient has abnormality of the gene on which Herceptin works. for some other cancers. I have been attacked by the Texas Medical Board for going overboard and using a logical. and that’s how we got substantial success. We are dealing with 700 000 existing ingredients which have pharmaceutical activity. some other chemicals may promote cancer. which are causing cancer. For instance. they have started to realize that there is a need to identify what is causing cancer in every patient who is coming for treatment and to use the right combination of medications. The sample is sent to this laboratory. Herceptin was approved for the treatment of stomach cancer. Even today. That’s what we use in our practice. but identify the germs which cause pneumonia and treat the germs. When you run genomic analysis. The crowd of oncologists learns the medicine by heart without understanding of what’s going on. To share or copy this article. recognized by the NCI. And it’s covered by insurance. the doctors realized that what they need to do is treat microorganisms which are causing the infection rather than the name of infection. NO. Some of these chemicals may help us to fight cancer. this approach still persists. In order to do it right. Once he receives the results. ATHM: Do you find diet and supplements effective in treatment of cancer? Which supplements do you recommend to patients? Dr Burzynski: Diet is a combination of chemicals. Or you receive another suggestion—this patient absolutely should avoid dietary ingredients which contain too much Conversations With Stanislaw R. then we can have very good results. There are over 40 medications that are available now. We try to use 60 the group of medications which work as genomic switches. and this is not the same when the gene is mutated. They can also be amplified. and certainly you have chemicals which could be very effective in the treatment of cancer. What is needed is a rational approach. And frankly speaking. This is done by one of the best laboratories in the world. It’s not so difficult to understand. 20 years ago. then we can identify the medications which are the best combination for this particular patient. we have a totalitarian approach toward treatment: Everybody should receive the same regimen for the same name of cancer. you can have good results and you can save a lot of money. very. every patient who comes to the clinic is advised to have genomic analysis of tissue taken from the tumor. They turn on the genes which fight cancer. Usually. But then if you learn how to use the proper switch to activate the gene then you have a powerful weapon against cancer. Some doctors feel now that perhaps in 10 years oncology will completely change and every patient will have genomic analysis and be treated with a different plan which is designed for him. The genes can be mutated. But what is not so understandable is that there is a system of genomic switches—called epigenome—which can switch off the activity of the gene or turn the gene on without changing the structure of the gene. It was suspected some time ago that it will take 30 years to introduce such change. VOL. you receive results suggesting that vitamin D could be quite helpful for one patient. oncologists will attack you if you try to use Herceptin for something else. and they send us the result. But of course. The first medication which worked on genes was Herceptin for the treatment of breast cancer. To subscribe. 3 . ATHM: So is this what you mean about driver genes and designer treatment for your patients? Dr Burzynski: Yes. This is foolish. they were used for the treatment of infections such as pneumonia or kidney infections or whatever. So now there’s the beginning of big change. PhD ALTERNATIVE THERAPIES. Burzynski. you also receive indication of which dietary ingredient could be helpful. scientific approach toward treatment of the genes. We need to identify these genes.” If we are successful. and we need to add additional medications which are now available which work on other genes. We can also identify the medications which should be avoided because they are unlikely to work. this is not sufficient. and it may lose the activity. You have some other genes involved in cancer. The laboratory runs the analysis of gene activity for the entire genome of 24 000 genes. ATHM: And do you provide genomic analysis for your patients? Dr Burzynski: No. Antineoplastons are genomic switches which work on about 100 different genes that are crucial in development of cancer. very few medications could work on genes at that time. But after a number of years. If you identify which patients will benefit from a particular medication. And then we can have success. visit alternative-therapies. this is tissue which was obtained when the patient had biopsy. When antibiotics were introduced for the first time. That’s what we pioneered. You have to know what to do. there is no financial burden for the patient. However.
and they would like to join us. They don’t believe something can come from a small clinic.This article is protected by copyright. please visit our clinic. We are talking about the brightest guys. All of this comes together as the scientific approach for the treatment of cancer. But this crowd also will change if the breakthrough comes. For about 75% of patients. you have to find out what is the best for this individual patient. ATHM: Are there supplements or food components that you recommend that people with cancer should avoid? Dr Burzynski: Well. just to make the next generation of antineoplastons.burzynskiclinic. just to give you an example. If you are talking about. NO.com L-glutamine. 3 61 . visit alternative-therapies. 18. You are dealing with 100 000 varieties. And every patient who comes to us has a dietary consultation where we give him an indication of which diet is the best for him and which supplements he should use. To subscribe. Every patient seems to have different combination of genes which cause the cancer. That’s our main task. We are treating patients together with oncologists from all over the world. Of course. and that’s what we do.com ALTERNATIVE THERAPIES. MD. To share or copy this article. you must look for driver genes—genes which are crucial to the development of cancer. We have young oncologists who are very interested in what we do. but only a few of these doctors will pay attention to what I have to say because I am not from a big medical institution. ATHM: Do you think that understanding in the medical community about your research is improving with time or evolving? Dr Burzynski: Absolutely. and then our approach will be accepted. will stop. That is what we are looking for. please visit copyright. a small research center. as a general rule we have to avoid free sugars because they are used to produce energy in cancer cells. PhD ATHM: Has your research taken on any new directions lately? Dr Burzynski: Yes. breast cancer. Our goal is to identify the most important gene. Of course. not much good came from these institutions within the last decade. L-glutamine is an amino acid to be avoided because it’s also extremely important for the development of cancer. They all assume research must come from a big pharmaceutical company or big institutions. and the number of those who would like to be trained in our strategy is increasing all the time. http://www. for instance. The rest of the club does not understand what we do at all and hate us. and the tumors will disappear. Burzynski. ATHM: Have you had young scientists come to you because they are excited and interested by your work? Dr Burzynski: Absolutely. Once we are successful. We are working on the next generation of antineoplastons by using nano technology and techniques. If you consider 24 000 genes which constitute a cancerous genome. Use ISSN#1078-6791. We have young scientists who are working in laboratories. mAY/JUNE 2012. They hate to see our good results. But really. But a number of doctors are beginning to understand what we do. We have a group of about 100 top oncologists. So at this moment. I have no doubt about it. They would like to get rid of us. ATHM: Any last thoughts? Dr Burzynski: Hopefully the problems which we face now. ATHM: Are different diets appropriate for different types of cancer? Dr Burzynski: For every patient. then the network of genes which caused the cancer will collapse. the senseless attacks. which is an amino acid that can stimulate some types of cancer.com. the driver gene. we have to convert oncologists one by one. then the amount of combinations is astronomical. Conversations With Stanislaw R. Some of the brightest oncologists are working together with us. It’s not for cancer. if you would like to do it right. There are many other genes that are normal and are simply working in the direction of driver genes. We would like to improve the activity and make the treatment much easier. Unfortunately. We have oncologists coming to us from various countries almost all the time to learn how to use our approach. If somebody would like to know more about our work. you are not dealing with say five or seven varieties of breast cancer. I am giving lectures at the oncology congresses. VOL.
This action might not be possible to undo. Are you sure you want to continue?
We've moved you to where you read on your other device.
Get the full title to continue listening from where you left off, or restart the preview.